Published in J Clin Exp Hepatol on June 06, 2014
Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma. J Surg Oncol (2016) 0.82
Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol (2015) 0.78
The NKD1/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells. Sci Rep (2016) 0.77
Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma. Onco Targets Ther (2016) 0.76
Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol (2016) 0.76
Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression. BMC Cancer (2015) 0.75
Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol (2015) 0.75
A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncol Lett (2015) 0.75
Does tumor size improve the accuracy of prognostic prediction in patients with esophageal squamous cell carcinoma after surgical resection? Oncotarget (2016) 0.75
The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget (2017) 0.75
Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol (2016) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Extrahepatic metastases of hepatocellular carcinoma. Radiology (2000) 4.82
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol (2002) 2.47
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer (1993) 2.15
Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer (1989) 1.85
Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer (2000) 1.82
Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials (2009) 1.67
Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut (2002) 1.66
Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med (2007) 1.40
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol (2011) 1.22
Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology (2000) 1.13
Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India. Oncology (2009) 1.03
Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol (2007) 1.03
Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM (2008) 0.96
Comparison of staging systems of hepatocellular carcinoma. HPB Surg (2011) 0.85
Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma. Trop Gastroenterol (2011) 0.84
[Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein]. Nan Fang Yi Ke Da Xue Xue Bao (2012) 0.82
HCC: what's the score. Gut (2002) 0.79
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol (2014) 1.08
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02
Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver. J Clin Exp Hepatol (2014) 0.96
Portal cavernoma cholangiopathy-clinical characteristics. J Clin Exp Hepatol (2013) 0.88
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol (2015) 0.85
Combination Therapy in Severe Alcoholic Hepatitis-Doesn't Really Work. J Clin Exp Hepatol (2013) 0.76
Reversibility of hepatic fibrosis and cirrhosis-another evidence. J Clin Exp Hepatol (2013) 0.75
Corrigendum to "Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: Update 2016" [J. Clin. Exp. Hepatol. 6 (2016) 119-145]. J Clin Exp Hepatol (2016) 0.75
Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist? J Clin Exp Hepatol (2017) 0.75
Toward a Better Definition of Acute-on-Chronic Liver Failure. J Clin Exp Hepatol (2017) 0.75